Diethyl-1-indanylmalonat | 52957-54-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: Diethyl-1-indanylmalonat
• 英文别名: Indan-1-malonsaeure-diethylester；Indan-1-yl-malonester；Indan-1-yl-malonsaeure-diethylester；indan-1-yl-malonic acid diethyl ester；Indan-1-yl-malonsaeure-diaethylester；Diethyl indan-1-ylmalonate；diethyl indanylmalonate；diethyl 2-(2,3-dihydro-1H-inden-1-yl)propanedioate
• CAS: 52957-54-7
• 化学式: C₁₆H₂₀O₄
• 分子量: 276.332
• InChiKey: OEOBWIYBWVAESE-UHFFFAOYSA-N

物化性质

• 沸点：
  146 °C(Press: 1 Torr)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Diethyl-1-indanylmalonat 在 氢氧化钾 作用下， 以 乙醇 为溶剂， 生成 2,3-二氢-1H-茚-1-乙酸乙酯
  参考文献：
  名称：

  与色胺有关的茚满乙胺的制备及药理筛选

  摘要：

  摘要制备了一系列的单和双-N-取代的2-（1-茚满基）-乙基地雷，并筛选了抑制单价地雷氧化酶和5-羟色胺的作用。描述了制备它们的合成方法，并讨论了用于筛选其的方法以及发现的活性。

  DOI：

  10.1002/jps.2600630608
• 作为产物：
  描述：

  2,3-二氢-1H-茚-1-醇 在 氯化亚砜 、 苯 作用下， 生成 Diethyl-1-indanylmalonat
  参考文献：
  名称：

  Protiva et al., Collection of Czechoslovak Chemical Communications, 1951, vol. 16/17, p. 331,341

  摘要：

  DOI：

文献信息

• .beta.-thiopropionyl-aminoacid derivatives and their use as
  申请人：SmithKline Beecham p.l.c.

  公开号：US06048852A1

  公开（公告）日：2000-04-11

  A method of treatment of bacterial infections in humans or animals which comprises administering, in combination with a .beta.-lactam antibiotic, a therapeutically effective amount of an amino acid derivative of Formula (I) or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, ##STR1## wherein: R is hydrogen, a salt forming cation or an in vivo hydrolysable ester-forming group; R.sub.1 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms or by a mercapto, (C.sub.1-6)alkoxy, hydroxy, amino, nitro, carboxy, (C.sub.1-6)alkylcarbonyloxy, (C.sub.1-6)alkoxycarbonyl, formyl or (C.sub.1-6)alkylcarbonyl group, (C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl(C.sub.1-6)alkyl, heterocyclyl or heterocyclyl(C.sub.1-6)alkyl; R.sub.2 is hydrogen, (C.sub.1-6)alkyl or aryl(C.sub.1-6)alkyl; R.sub.3 is hydrogen, (C.sub.1-6)alkyl optionally substituted by up to three halogen atoms, (C.sub.3-7)cycloalkyl, fused aryl(C.sub.3-7)cycloalkyl, (C.sub.3-7)cycloalkyl(C.sub.2-6)alkyl, (C.sub.2-6)alkenyl, (C.sub.2-6)alkynyl, aryl, aryl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, heterocyclyl or heterocyclyl-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n, where m is 0 to 3, n is 1 to 3, each R.sub.10 and R.sub.11 is independently hydrogen or (C.sub.1-4)alkyl and X is O, S(O).sub.x where x is 0-2, or a bond; R.sub.4 is hydrogen, or an in vivo hydrolysable acyl group; and R.sub.5 and R.sub.6 are independently hydrogen and (C.sub.1-6)alkyl or together represent (CH.sub.2).sub.p where p is 2 to 5. Some compounds are claimed per se.

  一种治疗人类或动物细菌感染的方法，包括与β-内酰胺类抗生素联合给药，给予公式(I)的氨基酸衍生物的治疗有效量或其药用可接受的盐、溶剂化合物或体内可水解酯的治疗有效量，其中：R为氢、形成盐的阳离子或体内可水解酯形成基团；R.sub.1为氢、(C.sub.1-6)烷基，可选地被高达三个卤素原子或巯基、(C.sub.1-6)烷氧基、羟基、氨基、硝基、羧基、(C.sub.1-6)烷基羰氧基、(C.sub.1-6)烷氧羰基、甲酰基或(C.sub.1-6)烷基羰基取代，(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基(C.sub.1-6)烷基，杂环烷基或杂环烷基(C.sub.1-6)烷基；R.sub.2为氢，(C.sub.1-6)烷基或芳基(C.sub.1-6)烷基；R.sub.3为氢，(C.sub.1-6)烷基，可选地被高达三个卤素原子取代，(C.sub.3-7)环烷基，融合的芳基(C.sub.3-7)环烷基，(C.sub.3-7)环烷基(C.sub.2-6)烷基，(C.sub.2-6)烯基，(C.sub.2-6)炔基，芳基，芳基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，杂环烷基或杂环烷基-(CHR.sub.10).sub.m --X--(CHR.sub.11).sub.n，其中m为0至3，n为1至3，每个R.sub.10和R.sub.11独立地为氢或(C.sub.1-4)烷基，X为O，S(O).sub.x，其中x为0-2，或键；R.sub.4为氢，或体内可水解的酰基；R.sub.5和R.sub.6独立地为氢和(C.sub.1-6)烷基，或一起代表(CH.sub.2).sub.p，其中p为2至5。一些化合物本身被要求。
• 4-Substituted-3-hydroxy-3-pyrroline-2,5-dione inhibitors of glycolic
  申请人：Merck & Co., Inc.

  公开号：US04342776A1

  公开（公告）日：1982-08-03

  Novel 4-substituted-3-hydroxy-3-pyrroline-2,5-diones are disclosed which inhibit glycolic acid oxidase and thus are useful in the treatment and prevention of calcium oxalate kidney stone formation. A novel process for their preparation is also disclosed.

  本发明揭示了一种新型的4-取代-3-羟基-3-吡咯烷-2,5-二酮，该化合物能够抑制醛酸氧化酶，因此在治疗和预防钙草酸肾结石形成方面具有用处。同时，本发明还揭示了一种制备该化合物的新方法。
• Electrolytic Reductive Coupling. XIII.¹ Intramolecular Reductive Coupling. Electrohydrocyclization²
  作者：James D. Anderson、Manuel M. Baizer、John P. Petrovich

  DOI：10.1021/jo01350a002

  日期：1966.12
• Mann,G., Journal fur praktische Chemie (Leipzig 1954), 1963, vol. 20, p. 210 - 218
  作者：Mann,G.

  DOI：——

  日期：——
• Moffett; Hart, Journal of the American Pharmaceutical Association (1912), 1953, vol. 42, p. 717
  作者：Moffett、Hart

  DOI：——

  日期：——